Interestingly, senicapoc, a Gardos channel inhibitor that maintains ion trafficking and preserves volume homeostasis, has been investigated for sickle cell disease and hereditary xerocytosis, with promising findings [31,32]. The gene discussed is KCNN4; the disease is sickle cell disease.